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Chondral and osteochondral lesions represent one of the most challenging and frustrating
scenarios for the orthopedic surgeon and for the patient. The lack of therapeutic
strategies capable to reconstitute the function and structure of hyaline cartilage and to
halt the progression toward osteoarthritis has brought clinicians and scientists together,
to investigate the potential role of tissue engineering as a viable alternative to current
treatment modalities. In particular, the role of bioprinting is emerging as an innovative
technology that allows for the creation of organized 3D tissue constructs via a “layer-
by-layer” deposition process. This process also has the capability to combine cells and
biomaterials in an ordered and predetermined way. Here, we review the recent advances
in cartilage bioprinting and we identify the current challenges and the directions for future
developments in cartilage regeneration.
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Introduction
Orthopedic surgeons commonly face clinical and surgical challenges for which current therapeutic
strategies are not able to provide a satisfactory result. An example are young patients with large
osteochondral defects due to injury or osteochondritis dissecans, which represents a difficult and
frustrating clinical scenario for both the patient and the surgeon. Previous hyaline cartilage damage
has been reported to predispose individuals to osteoarthritis, possibly due to the limited capacity of
hyaline cartilage to repair itself (1).
The inability to halt degenerative changes in the articular surface in patients with chondral
and osteochondral lesions has brought scientists, clinicians, and surgeons together to tackle the
difficulties in cartilage tissue engineering. The goal of such collaboration is to produce mature
hyaline cartilage that can maintain its physical and functional properties in the long term, without
accelerated degeneration that may lead to arthritic changes.
Microfractures, mosaicplasty, and osteochondral allografts are the most common solutions
for a young patient with an osteochondral defect. Options like membrane autologous chon-
drocyte implantation (MACI) and other autologous chondrocytes implantation techniques have
failed to demonstrate sufficient superiority over the former techniques (2–6) leading to a
loss of support from important jurisdictional advisory committees because of the large cost
differential (7).
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Tissue engineering has the potential to address the issue of
osteoarticular loss and may provide a viable alternative to current
treatment modalities. For example, established in vitro and in vivo
tissue-engineering techniques have successfully led to the creation
of living cartilage (8–11) and bone (12, 13).
The capability to re-growth living tissue at the core of their
complexity remains amajor challenge due to the differences in cell
types, matrix components, and organization (14), and this is par-
ticularly true for hyaline cartilage regeneration. Tissue engineering
can yield three-dimensional (3D) tissue-like constructs, which are
known to be important for organ development and in addition
these can serve as “experimental platforms for biological studies
and drug screening, and as implants for clinical application” (15).
Bioprinting can be defined as an “innovative technology that
allows for the generation of organized 3D tissue constructs via a
layer-by-layer deposition process that combines cells and bioma-
terials in an ordered and predeterminedway” (16, 17). Bioprinting
of scaffolds and cells is emerging as an important way of recreating
themicrophysical environment and the relationship between cells,
their matrix and local anatomy. There is a great variety of 3D
printing techniques, each with pros and cons and with particular
indications to specific tissues.
The goal of this review is to focus on recent advances in car-
tilage bioprinting and to identify the current challenges and the
directions for future developments in cartilage regeneration.
Cartilage: Why is it Difficult to Recreate the
Perfect Articular Surface
Without blood vessels, nerves, and lymphatics, and with only one
type of cells (18, 19), mature hyaline cartilage appears to be easy
to create in laboratory. However, these characteristics also mean
that cartilage injuries cannot heal spontaneously, and that any type
of repair will be characterized by fibrocartilage, which represents
a “scar-type” tissue (20, 21). This tissue lacks the properties that
make hyaline cartilage so unique including its resistance to shear,
compression, and load, thus leading to degenerative changes and
arthritis (22).
Despite its simple appearance, cartilage is, in fact, a tissue that
shows great heterogeneity, and is characterized by a composition
that exhibits differences depending on the depth of the tissue.
Articular cartilage can be divided into three zones: the “superfi-
cial zone” (SZ) represents the top 10–20% (area in contact with
synovial fluid); just deep to it, the “middle zone” (MZ) represents
the next 40–60% of the cartilage, and, finally, the “deep zone”
(DZ) the bottom 30–40%, which then is in direct contact with
the subchondral bone. The SZ is characterized by the highest cell
density, the lowest amount of glycosaminoglycans (GAGs) (23),
and the lowest biosynthetic activity (24). Moving deeper from the
SZ, there is a progressive decrease in cell density and an increase in
the amount of GAGs (23), which results in the greatest amount of
GAGs and the lowest cell density in the DZ. A high concentration
of GAGs determines an increase in the compressive modulus of
the tissue, which therefore is at its peak in the DZ (25).
With regards to cell distribution and morphology, chondro-
cytes in the different zones differ. In the SZ, cells are small and flat-
tened, while in DZ, cells are larger and round (26). Furthermore,
collagen fiber alignment shows a very characteristic “arcade-like
structure” (27): collagen fibers, in fact, originate from the calcified
cartilage in a direction perpendicular to the joint surface, and
then change their orientation in the MZ to become parallel to
the articular surface in the superficial layer. This specific dis-
position of collagen fibers, together with the distribution of the
proteoglycan aggregates between the fibrils, provides the tissue
with unique biomechanical characteristics, which combines com-
pressive stiffness, resilience, and shear resistance. Additionally,
different types of proteins are present in the articular cartilage, and
their secretion and prevalence differs among zones; in the SZ, the
most represented proteins are clusterin (28, 29), proteoglycan-4
(PRG4), also known as superficial zone protein (SZP) or Lubricin
(30) and Del-1 (31), while in MZ, cartilage intermediate layer
protein (CILP) (32, 33) is at its peak. On the other hand, cartilage
oligomeric matrix protein (COMP) is mainly seen in MZ and
DZ (34, 35). The specific distribution of these proteins probably
contributes to the “zone-specific functionality” of the cartilage
(Figure 1).
It seems clear that the vast heterogeneity of articular cartilage
makes it a tissue much more complex than initially thought to
engineer in vitro.
A recent review on cartilage regeneration using zonal chondro-
cyte subpopulations has concluded that the attempted restoration
of the native tissue organization of articular cartilage has had very
limited results to date (36). It is well-known that the topographical
heterogeneity in biochemical and structural ECM characteristics
of articular cartilage is mainly due to the influence of biome-
chanical load and the microenvironment (37); therefore, some
authors question strategies based on the use of zonally harvested
cells, considering these as overcomplicated and potentially even
inherently ineffective.
On the other hand, an approach that is based on the use of a
single cell source coupled with the adequate biochemical and/or
biomechanical stimuli can prove to be more effective and simpler.
Another promising approach for tissue engineering is the com-
bination of a structure that shows biomechanical characteristics
similar to the natural environment, in order to create a similar
force dissipation pattern using “juvenile” cells, such as mesenchy-
mal stem cells (MSCs) or chondroblasts. This approach seems
feasible, and, in fact, it has been shown that combining different
biomaterials with a “smart scaffold design” can potentially affect
the deposition of extracellular matrix (ECM) by influencing cell
alignment (38). For the fabrication of such complex multiple-
material structures, advanced manufacturing techniques (Bio-
printing) have been shown to be useful (39–41) and, potentially,
the way of the future.
Types of Bioprinting: What Works for
Osteoarticular Tissues
Considering the inherent shortcomings of conventional scaffold-
based tissue repair, a new bio-fabrication approach, termed
“three-dimensional (3D) bioprinting,” has been introduced in
regenerative medicine (16). Differing from “subtractive manufac-
turing” traditionally used to create scaffolds (i.e., creating a shape
by chipping away parts from a large block), the new emerging
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FIGURE 1 | H&E stain and schematic representation of hyaline cartilage morphology and structure. SZ, superficial zone; MZ, middle zone; DZ, deep zone;
CZ, calcified zone; SB, subchondral bone. Picture used with permission obtained from J Cytochem Biochem.
technology is “additive manufacturing” (AM), which involves
the ability to create objects from the bottom-up. A 3D printer
is therefore a “computer controlled robotic system that creates
three-dimensional objects through the layer-by-layer addition of
material” (42). Using 3D printing techniques, the time required to
modify a test product is dramatically reduced. From this, the term
“Rapid Prototyping” is used.
Technological advances in the fields of automation, miniatur-
ization, and computer-aided design and machining have led to
the development of bioprinting (16–40). Applications of rapid
prototyping in regenerative medicine allow tissue engineers to
precisely control the scaffold structure, and hence, guide cells to
form a functional tissue (43, 44).
With the boom of 3D bioprinting and new engineering tech-
nologies to create scaffolds of different materials and shape, there
has been a wide development of printers and machines. Several
AM technologies that allow the fabrication of customized parts
and devices with geometrically complex structures have been
applied in the field of bio-fabrication (45). These include fused
deposition modeling (FDM) (46, 47), pneumatic extrusion print-
ing, stereolithography (48–50), extrusion printing gels (51), inkjet
printing (52–55), and selective laser sintering (SLS) (56, 57). Each
of these methods has advantages and disadvantages; however, a
detailed discussion of these is beyond the scope of this review.
With regards to cartilage regeneration, hydrogel-based scaffolds
are the main materials used given their inherent compatibility
with chondral tissue; therefore, inkjet and pneumatic extrusion
printers are the most commonly used machines in this field of
tissue engineering.
With advances in AM-based printing technologies, a certain
degree of material specificity can be also engineered, and this
includes highly ordered interconnected porous polymer network
structure (58).Moreover, the ability to print cells together with the
scaffold can facilitate the production of biomaterial that can have
characteristics similar to native tissue. The development of such
a technology able to combine the deposition of specific cell types
with the simultaneous printing of biomaterials can, potentially, be
useful in the creation of cartilaginous tissue with different zonal
distribution (59).
All the printing techniques described above have been used to
print cells, and, although with some differences, all have demon-
strated to be safe and reliable with regards to cells survival and
proliferation.
Bioprinting Cartilage
Hydrogels are defined as “water-swellable, yet water-insoluble,
cross-linked networks” that can provide multiple advantages in
tissue engineering as cell carriers for the creation of a multiple
tissues. The 3D environment that they provide is able to maintain
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a high-water content, which resembles biological tissues and,
therefore, facilitates cell proliferation (60). There are a multitude
of natural polymers (i.e., collagen, chitosan, hyaluronic (HA)
acid, silk proteins, gelatin and alginates) that are widely used
as hydrogel materials for tissue-engineering applications, in
particular, for cartilage tissue engineering (61, 62). Biocompatible
hydrogels have the ability to induce a phase change from liquid
to (semi-)solid by crosslinking (63), and for this reason these
materials show high potential for 3-D bioprinting. Crosslinking
can be induced chemically (e.g., Ca2+ to cross link alginate),
thermally, or using UV or visible light with the addition of
appropriate initiators.
In cartilage bioprinting, it has been shown that “chondrocytes
and stem cells encapsulated within alginate hydrogels remain
viable and metabolically active” (64). The main limitation of
hydrogels for tissue engineering is their inability to maintain
a uniform 3D structure. To overcome this problem, hydrogels
may be coupled with synthetic biomaterials, such as poly-glycolic
acids (PGA), polycaprolactone (PCL), methacrylate, hydroxya-
patite, and others. A combination of hydrogel, in the form of
alginate–gelatin, and hydroxyapatite can be used to print stable
3D constructs for bone regeneration, and this combination also
allows living humanmesenchymal stem cells (hMSCs) to be added
in the bioink. This approach has shown that, after 3 days of
in vitro culture, cell viability remains high despite the printing and
crosslinking processes (65).
Hyaluronic acid (HA) is an essential component of the cartilage
ECM and “its structural and biological properties mediate cellular
signaling, wound repair, morphogenesis, and matrix organiza-
tion” (66). Recently, HA has, in fact, been used more and more
often as an important “building block” for the creation of new
biomaterials in cell therapy approaches, three-dimensional (3D)
cell culture, and tissue engineering (67–69). HA has been widely
used as hydrogel for cartilage regeneration, as an ECM-mimetic
hydrogel with good results (70–72).
Many studies have used materials, such as PCL or polylac-
tic acid (PLA), together with hydrogels for the creation of a
printable material, compatible with cartilage cells. PCL was suc-
cessfully used for the creation of 3D-printed scaffolds using a
“layer-by-layer” deposition strategy and coupled with “chondro-
cyte cell-encapsulated alginate hydrogel” (73). This study showed
the formation and synthesis of cartilaginous matrix without any
adverse tissue response.
In another study, PCL fibers were deposited using electro-
spinning techniques, which were alternated with inkjet printing
of chondrocytes (derived from rabbits) and suspended in a fib-
rin–collagen hydrogel. This strategy was used to fabricate a tissue
construct of 1mm thickness, made of five-layers of material com-
bined together. The authors show that this fabricated constructs
allowed the formation of cartilage-like tissues both in vitro and
in vivo, and this was demonstrated by the deposition of type II
collagen and GAGs (74).
Methacrylate containing materials are commonly used with
hydrogels for the regeneration of cartilage. An example is the
use of Poly(ethylene glycol) dimethacrylate (PEGDMA) printed
together with human chondrocytes to repair defects in osteo-
chondral plugs (3D biopaper) in “layer-by-layer” assembly (75).
In this study, an osteochondral defect was created in vitro in
the center of an osteochondral plug, and using inkjet printing
methods, PEGDMA and chondrocytes were printed within the
defect. The authors demonstrated that delivering chondrocytes
and biomaterial scaffolds to precise target locations in a 3D for
zonal cartilage engineering is a feasible strategy of fabricating
cartilage structures with anatomic characteristics.
Cells can also be printed by encapsulating them into micro-
carriers. Levato and colleagues have shown that cell-laden PLA
micro-carriers can be encapsulated in gelatin methacrylamide-
gellan gum bioinks, and using this approach they have fabricated a
bi-layered tissue models that included not only the cartilage tissue
but also the bone compartment (14).
Recently, Kesti has shown that a scaffoldmade of the thermore-
sponsive polymer poly(N-isopropylacrylamide) grafted hyaluro-
nan (HA-pNIPAAM) with methacrylated hyaluronan (HAMA)
could be used for creating cartilage in vitro. The HAMA-HA-
pNIPAAM was cross-linked using UV light. Bovine chondro-
cytes were cultured on top the scaffold and showed 98% viability
after 7 days of culture, demonstrating that the combination of
hydrogel and HAMA was not toxic and that UV light does not
affect cells viability (76). However, when cells were printed in
the context of the gel, the survival rate was severely affected (77).
Cells within the gel tend to show a limited interaction between
each other, and this could be explained by the nature of alginate,
which does not allow for strong cell–cell communication. Thus,
although there were some successful reports about bioprinting
of cell-printed structure, great concern remains regarding the
minimal cells–material interactions and inferior tissue forma-
tion compared to tissues that have not been printed and cross-
linked (78).
It would seem ideal if cells are provided the natural microen-
vironment that exhibits similar characteristics to their original
tissue, such as decellularized extracellular matrix (dECM). The
recapitulation of ECM, in fact, has become the focus of cartilage
engineering in recent years. It is hypothesized that chondrocytes
would change their function and morphology based on the ECM,
therefore being able to provide the appropriate ECM structure
is now considered paramount in cartilage tissue engineering. So
far, however, the complexity of natural ECM has not been able
to the replicated by the majority of the matrix materials used for
bioprinting and thus these materials have not demonstrated yet
their ability to reconstitute the intrinsic cellular morphologies and
functions of articular cartilage. Recently, a bioprinting method
for printing of cell-laden structure with novel decellularized ECM
(dECM) bioink capable of providing an optimized microenvi-
ronment conducive to the growth of 3D structured tissue has
been described (78). In this study, printed cell dECM constructs
revealed high levels of cell viability, differential lineage commit-
ment, and ECM formation. With this approach, the authors were
able to generate a tissue in vitro that had analog characteristics
of the original tissue, with either adipogenic or chondrogenic
potential, based on the type of dECM used.
Finally, it has been proposed that Bio-fabrication of tissues can
be done without the use of a 3D scaffold. Laser printing of stem
cells for bio-fabrication of Scaffold-Free Autologous Grafts for
bone and cartilage tissue engineering has been shown by Gruene
et al. to be a reliable way of producing cartilage in vitro (79). Using
a natural hydrogel consisting of plasma and alginate, stem cells
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have been successfully printed in vitro and differentiated toward
mature cartilage and bone.
Current Challenges
Although research in cartilage bioprinting is growing exponen-
tially, there is still a lack of in vivo studies that can ascertain the
capability of the printed material to regenerate hyaline cartilage.
In particular, the big challenge remains the long-term stability
of the engineered tissue. So far, no studies have demonstrated
the superiority of these techniques to the currently used clinical
strategies; and therefore, we are still far away from the use of
bioprinting in clinic.
One of the difficulties is to obtain ethical approval for the har-
vest and expansion of stem cells in laboratory and, subsequently,
their use in surgery. The phrase “bench-to-bedside” is commonly
used to describe the translation of basic discoveries, such as those
on stem cells to the clinic for therapeutic use in human patients.
This is still a very difficult obstacle to overtake before the discov-
eries made in laboratory can be safely and successfully translated
in human patients (80, 81).
Another challenge is the matching of the bench-based printed
material to the operating room. Despite the advances in 3D
anatomic reconstructions, the in vitro printed material will not be
able to perfectly match the defect that needs to be regenerated.
The current in vivo studies are based onman-made regular defects
that can be filled with a scaffold made of the exact shape and
dimension. In clinics, however, this is not the case, and although
more defined defects can be created (such as the ones made for
mosaicplasty), this is not ideal as it further increases the area that
needs to be repaired. Printers are big machines connected with
highly sophisticated computers, and at this stage, the only solution
is to obtain the material in laboratory and subsequently transfer it
to the patient. “In situ” bioprinting has been performed by Cohen
and colleagues, who used an explanted articular surface from a
calf and, by holding it on a support, printed “ex vivo” alginate
hydrogel for bone and cartilage repair (82). Even in this case,
however, the machine used for the printing is too cumbersome
to be used in an operating room. There is the need, therefore,
to create a printing system that can be used “live” during the
surgical procedure, directly by the surgeon. This could represent
the future for tissue engineering using bioprinting techniques in
cartilage regeneration, as it would avoid some laboratory-based
passages, which would represent more ethical challenges. Using a
single direct approach, also, the need for two (or more) surgical
interventions will be eliminated, with better compliance for the
patient and a quicker recovery time.
Overall, the possibilities that bioprinting brings to tissue engi-
neering are endless, and for the scientific community this is a very
exciting time. There is still some time towait for these technologies
to be available to the surgeons, but the findings so far are very
promising.
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